The connectivity map: Using gene-expression signatures to connect small molecules, genes, and disease

被引:3859
作者
Lamb, Justin
Crawford, Emily D.
Peck, David
Modell, Joshua W.
Blat, Irene C.
Wrobel, Matthew J.
Lerner, Jim
Brunet, Jean-Philippe
Subramanian, Aravind
Ross, Kenneth N.
Reich, Michael
Hieronymus, Haley
Wei, Guo
Armstrong, Scott A.
Haggarty, Stephen J.
Clemons, Paul A.
Wei, Ru
Carr, Steven A.
Lander, Eric S.
Golub, Todd R. [1 ]
机构
[1] MIT, Broad Inst, Cambridge, MA 02142 USA
[2] Harvard Univ, Broad Inst, Cambridge, MA 02142 USA
[3] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA
[4] Childrens Hosp, Dept Med, Boston, MA 02115 USA
[5] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02144 USA
[6] Harvard Univ, Sch Med, Boston, MA 02115 USA
[7] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA
[8] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA
关键词
D O I
10.1126/science.1132939
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
To pursue a systematic approach to the discovery of functional connections among diseases, genetic perturbation, and drug action, we have created the first installment of a reference collection of gene-expression profiles from cultured human cells treated with bioactive small molecules, together with pattern-matching software to mine these data. We demonstrate that this "Connectivity Map'' resource can be used to find connections among small molecules sharing a mechanism of action, chemicals and physiological processes, and diseases and drugs. These results indicate the feasibility of the approach and suggest the value of a large-scale community Connectivity Map project.
引用
收藏
页码:1929 / 1935
页数:7
相关论文
共 41 条
[1]   Efficient reversal of Alzheimer's disease fibril formation and elimination of neurotoxicity by a small molecule [J].
Blanchard, BJ ;
Chen, A ;
Rozeboom, LM ;
Stafford, KA ;
Weigele, P ;
Ingram, VM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (40) :14326-14332
[2]   Exploring the metabolic and genetic control of gene expression on a genomic scale [J].
DeRisi, JL ;
Iyer, VR ;
Brown, PO .
SCIENCE, 1997, 278 (5338) :680-686
[3]   17 ALPHA-ESTRADIOL IS A BIOLOGICALLY-ACTIVE ESTROGEN IN HUMAN-BREAST CANCER-CELLS IN TISSUE-CULTURE [J].
EDWARDS, DP ;
MCGUIRE, WL .
ENDOCRINOLOGY, 1980, 107 (04) :884-891
[4]   A gene expression signature that predicts the future onset of drug-induced renal tubular toxicity [J].
Fielden, MR ;
Eynon, BP ;
Natsoulis, G ;
Jarnagin, K ;
Banas, D ;
Kolaja, KL .
TOXICOLOGIC PATHOLOGY, 2005, 33 (06) :675-683
[5]   15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2) IS A LIGAND FOR THE ADIPOCYTE DETERMINATION FACTOR PPAR-GAMMA [J].
FORMAN, BM ;
TONTONOZ, P ;
CHEN, J ;
BRUN, RP ;
SPIEGELMAN, BM ;
EVANS, RM .
CELL, 1995, 83 (05) :803-812
[6]   Selective estrogen receptor modulators:: Discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells [J].
Frasor, J ;
Stossi, F ;
Danes, JM ;
Komm, B ;
Lyttle, CR ;
Katzenellenbogen, BS .
CANCER RESEARCH, 2004, 64 (04) :1522-1533
[7]   Development of a large-scale chemogenomics database to improve drug candidate selection and to understand mechanisms of chemical toxicity and action [J].
Ganter, B ;
Tugendreich, S ;
Pearson, CI ;
Ayanoglu, E ;
Baumhueter, S ;
Bostian, KA ;
Brady, L ;
Browne, LJ ;
Calvin, JT ;
Day, GJ ;
Breckenridge, N ;
Dunlea, S ;
Eynon, BP ;
Furness, LM ;
Ferng, J ;
Fielden, MR ;
Fujimoto, SY ;
Gong, L ;
Hu, C ;
Idury, R ;
Judo, MSB ;
Kolaja, KL ;
Lee, MD ;
McSorley, C ;
Minor, JM ;
Nair, RV ;
Natsoulis, G ;
Nguyen, P ;
Nicholson, SM ;
Pham, H ;
Roter, AH ;
Sun, DX ;
Tan, SQ ;
Thode, S ;
Tolley, AM ;
Vladimirova, A ;
Yang, J ;
Zhou, ZM ;
Jarnagin, K .
JOURNAL OF BIOTECHNOLOGY, 2005, 119 (03) :219-244
[8]  
Glaser KB, 2003, MOL CANCER THER, V2, P151
[9]   Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring [J].
Golub, TR ;
Slonim, DK ;
Tamayo, P ;
Huard, C ;
Gaasenbeek, M ;
Mesirov, JP ;
Coller, H ;
Loh, ML ;
Downing, JR ;
Caligiuri, MA ;
Bloomfield, CD ;
Lander, ES .
SCIENCE, 1999, 286 (5439) :531-537
[10]   BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90 [J].
Gorre, ME ;
Ellwood-Yen, K ;
Chiosis, G ;
Rosen, N ;
Sawyers, CL .
BLOOD, 2002, 100 (08) :3041-3044